New Therapeutic Options in the Management of
Chronic Heart Failure:Optimized Strategies
for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. Fortunately for patients with chronic HF, new and emerging therapeutic options have shown the promise for improving outcomes for these patients. Although multiple therapies have shown to lower mortality in patients with HF, their applications in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high.

Upon Completion of this activity, participants will be able to:

  • Summarize the mechanisms of action and different clinical attributes of new and emerging therapies for the management of chronic heart failure (HF)

  • Evaluate methods for individualizing chronic HF treatment strategies for patients based on specific patient-related factors to control symptoms, reduce hospitalizations, and prevent mortality in patients with reduced ejection fraction

  • Analyze the latest clinical trial data demonstrating the appropriate use of pharmacologic interventions in patients with chronic heart failure and reduced ejection fraction

  • Explore patient management and communication tools to activate the patient as a key member of the care team

Faculty: R. Scott Wright, MD
Professor of Medicine
Mayo Clinic


Dr. Wright serves as a consultant with AstraZeneca, Boehringer-Ingelheim, The Medicines Company, Regeneron and Sanofi. He also provides contractual services to the Mayo Clinic.  His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue